Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
May 01 2023 - 3:01PM
Business Wire
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced it
will release first quarter 2023 financial results after the market
closes on Monday, May 8, 2023.
Xencor management will host a webcast and conference call the
same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial
results and provide a corporate update.
The live webcast will be available under “Events &
Presentations” in the Investors section of the Company’s website
located at investors.xencor.com and will be archived for at least
30 days. Active participants in the conference call may receive
credentials for telephone access by registering at the following
link:
https://register.vevent.com/register/BI0da076297f5f4f3b920845d8b0e7f2d3.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
protein's structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230501005549/en/
Charles Liles cliles@xencor.com 626-737-8118
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Apr 2024 to May 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From May 2023 to May 2024